Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.
Lepage C, Phelip JM, Cany L, Barbier E, Manfredi S, Deguiral P, Laly M, Baconnier M, Jary M, Latrive JP, Terrebonne E, Lièvre A, Jafari M, Ben Abdelghani M, Ain JF, Breysacher G, Boillot-Benedetto I, Pelaquier A, Prost P, Ezenfis J, Rinaldi Y, Le Foll C, Berthelet O, Darut-Jouve A, Dahan L, Piche T, Lagasse JP, Bibeau F, Laurent-Puig P, Bouché O; PRODIGE 13 investigators/collaborators.
Lepage C, et al.
Ann Oncol. 2025 Dec;36(12):1468-1479. doi: 10.1016/j.annonc.2025.09.004. Epub 2025 Sep 17.
Ann Oncol. 2025.
PMID: 40972947
Clinical Trial.